Boehringer adds 250m value variant pact expanding cardio disease

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.

science

Sources

• T2Boehringer adds 250m value variant pact expanding cardio diseaseFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:07